Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
1. FDA approves Obagi® saypha® MagIQ™ hyaluronic acid gel for U.S. market. 2. Launch in 2026 is part of Waldencast's growth strategy. 3. Obagi Medical’s market expands to $4.2 billion potential by 2029. 4. Croma-Pharma’s MACRO Core Technology enhances product efficacy and safety. 5. Higher patient satisfaction expected with innovative injectable offerings.